TM
BBIO icon

Torren Management’s BridgeBio Pharma BBIO Stock Holding History

Torren Management’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.79K Hold
24
– – ﹤0.01% 598
2026
Q1 		$1.78K Hold
24
– – ﹤0.01% 589
2025
Q4 		$1.84K Buy
+24
New +$1.57K ﹤0.01% 1087

Other funds holding BBIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Fiera Capital (Canada)
Fiera Capital (Canada) Montreal, Quebec, Canada $27.6B AUM 23.56% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Torren Management's BBIO Position: Q2 2026 in Review

Torren Management held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 24 shares worth $1.79K. The position accounts for ﹤0.01% of the portfolio, ranked #598.

Torren Management first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $1.84K in Q4 2025. 190 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Torren Management held 24 shares of BridgeBio Pharma worth $1.79K as of Q2 2026.
  • Torren Management left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up ﹤0.01% of Torren Management's portfolio in Q2 2026, its #598 holding.
  • Torren Management first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • Torren Management's BridgeBio Pharma position peaked at $1.84K in Q4 2025.
  • 190 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Torren Management's 13F filing for Q2 2026, filed 10 Jul 2026.